New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDS5 vs Thymosin Beta-4

DS5 vs Thymosin Beta-4

Side-by-side comparison of key properties, dosing, and research.

Sleep Optimization
DS5
Recovery & RepairAnti-Aging & Longevity
Thymosin Beta-4
Summary
DS5 is a synthetic variant of the delta sleep-inducing peptide (DSIP), a nonapeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Like DSIP, DS5 is explored for sleep optimization, stress modulation, and circadian rhythm normalization, with proposed improvements in potency or stability over the parent molecule.
Thymosin Beta-4 is an endogenous 43-amino acid peptide that is the primary intracellular actin sequestering peptide. It promotes tissue repair, reduces inflammation, regenerates hair follicles, and protects cardiac tissue. Closely related to TB-500 (the active fragment), it is used for systemic tissue recovery and anti-aging.
Half-Life
Estimated 30-60 minutes (peptide degradation)
Not well characterized; likely similar to TB-500 (~1–2 hours)
Admin Route
Subcutaneous, Intranasal (research)
SubQ, IM
Research
Typical Dose
200-500 mcg per dose
5–10 mg
Frequency
Once nightly
2x per week (loading), then 1x per week (maintenance)
Key Benefits
  • Promotes delta-wave (deep) sleep and improves sleep quality
  • May reduce sleep onset latency
  • HPA axis modulation for stress reduction
  • Non-addictive sleep support without tolerance development
  • Potential circadian rhythm normalization
  • Explored for insomnia, chronic stress, and PTSD-related sleep disturbance
  • Systemic tissue repair and regeneration
  • Promotes cardiac recovery after myocardial infarction
  • Hair follicle regeneration and anti-hair-loss
  • Anti-inflammatory (systemic)
  • Wound healing acceleration
  • Neuroprotection after brain injury
  • Protects against ischemia-reperfusion injury
  • Anti-aging at cellular level
  • Synergizes powerfully with BPC-157
Side Effects
  • Generally well-tolerated in research subjects
  • Possible morning grogginess at higher doses
  • Mild blood pressure fluctuations reported with DSIP
  • Limited human safety data for DS5 specifically
  • Generally very well tolerated
  • Injection site reactions
  • Mild fatigue at initiation (repair signaling)
  • Rare: mild inflammatory response
  • +1 more
Stacks With